Previous Next

Left Ventricular-Arterial Coupling and Mechanical Efficiency

Optimal transfer of stroke volume from the LV to the arterial circulation requires appropriate matching of these mechanical systems. LV-arterial coupling has most often been described using a series elastic chamber model of the cardiovascular system ( Fig. 7-8 ). [128] The elastance of the contracting LV (Ees ) and the arterial vasculature (Ea ) is determined from LV end-systolic pressure-volume and


197


Figure 7-8 Left ventricular (LV) pressure versus LV volume diagrams during inferior vena caval occlusion and the definition of LV-arterial coupling. The LV maximal elastances of each pressure-volume diagram are used to calculate the slope (EES ) of the end-systolic pressure-volume relationship. Effective arterial elastance (EA ) is determined as the ratio of end-systolic arterial pressure and stoke volume during steady-state hemodynamic conditions. In the pressure-volume plane, EA represents the magnitude of the slope connecting end-systole to end-diastole. (Adapted from Hettrick DA, Pagel PS, Warltier DC: Desflurane, sevoflurane, and isoflurane impair canine left ventricular-arterial coupling and mechanical efficiency. Anesthesiology 85:403–413, 1996.)

end-systolic arterial pressure-stroke volume relationships, respectively.[128] [129] [130] The ratio of Ees to Ea defines coupling between the LV and the arterial circulation[128] [129] and provides a useful technique for assessment of the actions of drug, including volatile anesthetics, on LV-arterial matching in vivo.[131] [132] Analysis of the pressure-volume relationship also creates a framework for the study of LV mechanical efficiency defined by the ratio of stroke work (SW) to the pressure-volume area (PVA).[133]

The influence of volatile anesthetics on LV-arterial coupling and mechanical efficiency has been studied in the normal canine cardiovascular system but has not been described in models of heart failure. LV-arterial coupling may theoretically be maintained during anesthesia because declines in LV afterload may balance simultaneous reductions in myocardial contractility. Low concentrations of halothane (1 MAC), but not isoflurane, reduced Ees /Ea in barbiturate-anesthetized, acutely instrumented dogs, consistent with depression of mechanical coupling between the LV and arterial circulation.[134] However, isoflurane also decreased Ees /Ea at 2 MAC, suggesting that the vasodilating effects of this anesthetic were unable to compensate for the relatively greater declines in contractility. Desflurane, sevoflurane, and isoflurane maintained optimal LV-arterial coupling and mechanical efficiency as evaluated by Ees /Ea and SW/PVA at low anesthetic concentrations (0.9 MAC) by producing simultaneous declines in myocardial contractility and LV afterload ( Fig. 7-9 ).[41] However, mechanical matching between the LV and


Figure 7-9 Histograms depicting left ventricular-arterial coupling (Ees /Ea , top panel) and mechanical efficiency (SW/PVA; bottom panel) before (control 1 [C1]); during 0.6, 0.9, and 1.2 minimum alveolar concentrations (MAC); and after sevoflurane (control 2 [C2]). a, Significantly (P < .05) different from C1; b, significantly (P < .05) different from 0.9 MAC of sevoflurane; c, significantly (P < .05) different from 1.2 MAC of sevoflurane. (Adapted from Hettrick DA, Pagel PS, Warltier DC: Desflurane, sevoflurane, and isoflurane impair canine left ventricular-arterial coupling and mechanical efficiency. Anesthesiology 85:403–413, 1996.)

arterial vasculature and efficiency of total LV energy transfer to external stroke work degenerates at higher anesthetic concentrations, indicating that anesthetic-induced reductions in contractility are not appropriately balanced by declines in afterload. Halothane (<1.0 MAC) has also been shown to reduce the ratio of oscillatory-to-mean hydraulic power in vivo, indicating that this agent decreases LV mechanical efficiency as well.[135] Detrimental alterations in LV-arterial coupling produced by volatile anesthetics contribute to reductions in overall cardiac performance observed with these agents in vivo.

Previous Next